227 F. Supp. 3d 452
D.S.C.2017Background
- MDL centralized numerous lawsuits by women alleging Lipitor caused Type 2 diabetes; plaintiffs assert failure-to-warn and negligent marketing theories.
- Bellwether discovery and Daubert proceedings extensively litigated; court excluded plaintiffs’ general-causation experts for doses under 80 mg and excluded the bellwether specific-causation experts as unreliable.
- Plaintiffs were given multiple, repeated opportunities (CMO 65, 81, 82) to identify individual plaintiffs who could produce admissible expert or non‑expert evidence to survive summary judgment; virtually none did so; limited non‑expert filings were reviewed and found inadequate.
- Plaintiffs relied on alleged defendant admissions (internal email, labels, NDA data, foreign label) and on temporal/medical-record evidence to oppose summary judgment for <80 mg claimants.
- The court held: (1) state substantive law generally requires expert proof for medical causation in complex pharmaceutical cases; (2) associations/increased‑risk statements and single emails/labels do not substitute for required expert proof; and (3) summary judgment was granted for the plaintiffs listed in Appendix 1 (claims dismissed with prejudice).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether plaintiffs can survive summary judgment on general causation for Lipitor doses <80 mg without expert testimony | Admissions (emails, labels, NDA data, website, Japanese label) and association evidence suffice to show Lipitor can cause diabetes at lower doses | Expert evidence is required to show causation at medically complex questions; the cited materials show association, not causation | State law requires expert proof; the alleged admissions/association evidence do not create a genuine fact issue; summary judgment granted as to general causation for <80 mg plaintiffs |
| Whether party‑opponent admissions can substitute for expert testimony when state law requires experts | Admissions are admissible statements and thus may substitute for expert proof under Rule 56 | Allowing admissions to replace expert proof would contravene substantive state law and encourage speculative juror findings | Court rejects substitution theory: admissions that show mere association or are ambiguous cannot replace expert evidence required by state substantive law |
| Whether specific causation can be proved at trial without expert testimony (or with only temporal/medical‑record evidence) | Some plaintiffs argue non‑expert circumstantial evidence (timing, treatment records) can support specific causation; suggest remand to transferor courts | Temporal proximity and non‑expert medical records are inadequate for complex disease causation absent expert support | Specific causation requires expert proof in these jurisdictions; temporal association alone is legally insufficient; summary judgment granted where no admissible expert proof exists |
| Whether the MDL court should decide case‑specific summary judgments or remand to transferor courts | Plaintiffs urge remand for case‑specific causation adjudication | Defendants and court urge resolution in MDL for efficiency where common issues predominate and plaintiffs failed to come forward | MDL court may and should rule on common dispositive issues; court adjudicated omnibus motion and did not remand |
Key Cases Cited
- Celotex Corp. v. Catrett, 477 U.S. 317 (summary judgment standard and burden)
- Anderson v. Liberty Lobby, 477 U.S. 242 (jury issue and materiality standard)
- Daubert v. Merrell Dow Pharm., 509 U.S. 579 (expert admissibility framework and Rule 702 principles)
- Meridia Prods. Liab. Litig. v. Abbott Labs., 447 F.3d 861 (6th Cir. 2006) (label language may, in narrow circumstances, bear on causation assessment)
- Guinn v. AstraZeneca Pharm., 602 F.3d 1245 (11th Cir. 2010) (temporal association insufficient for differential diagnosis/specific causation)
- In re Mirena IUD Prod. Liab. Litig., 202 F. Supp. 3d 304 (S.D.N.Y. 2016) (admissions cannot substitute for required expert proof in complex medical causation cases)
- Gelboim v. Bank of Am. Corp., 135 S. Ct. 897 (MDL courts may enter final decisions on pretrial matters; remand rules)